Prescription drug · ANDA
Tazarotene NDC 73473-309
Tazarotene .5 mg/g · Gel · Cutaneous · Solaris Pharma Corporation
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 73473-309-10 | 73473030910 | 1 TUBE in 1 CARTON (73473-309-10) / 100 g in 1 TUBEMarketed from Jan 3, 2025 | |
| 73473-309-30 | 73473030930 | 1 TUBE in 1 CARTON (73473-309-30) / 30 g in 1 TUBEMarketed from Jan 3, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Tazarotene
- Generic name (nonproprietary)
- tazarotene
- Active ingredients
- Tazarotene — .5 mg/g
- Dosage form
- Gel
- Route
- Cutaneous
- Labeler
- Solaris Pharma Corporation
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 213644
- Marketing start
- Listing expires
- Other FDA classes
- Retinoids (Chemical structure)
- Identifiers
- Product ID 73473-309_d0c2fbdf-c1f1-43de-93ef-7da5e6279875SPL ID d0c2fbdf-c1f1-43de-93ef-7da5e6279875SPL set ID f1c98c4a-f101-4f3c-851a-39c827415c46RxCUI 313199, 313201UNII 81BDR9Y8PS
- Pharmacologic class
- Retinoid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N473473030910followed by a unit qualifier and the quantityPackage 73473-0309-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Tazarotene gel, 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement. ( 1.1 ) Tazarotene gel, 0.1% is indicated for the topical treatment of mild to moderate facial acne vulgaris. ( 1.2 ) Limitations of Use The safety of tazarotene gel use on more than 20% body surface area has not been established. ( 1.3 ) 1.1 Plaque Psoriasis Tazarotene gel, 0.05% and 0.1% are indicated for the topical treatment of patients with plaque psoriasis of up to 20% body surface area involvement. 1.2 Acne Vulgaris Tazarotene gel, 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate sever…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 213644
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Tazarotene | Tazarotene 1 mg/g | GelCutaneous | Solaris Pharma Corporation | 73473-310 |